Premium
Hepatosplenic gamma‐delta T‐cell malignant lymphoma: report of the first case in childhood, including molecular minimal residual disease follow‐up
Author(s) -
GARCIASANCHEZ F.,
MENÁRGUEZ J.,
CRISTOBAL E.,
CANTAI.EJO A.,
GIL J.,
ALGARA P.,
VICARIO J. L.
Publication year - 1995
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.1995.tb05221.x
Subject(s) - minimal residual disease , lymphoma , t cell receptor , bone marrow , medicine , gene rearrangement , disease , t cell , pathology , oncology , immunology , cancer research , biology , gene , immune system , genetics
Summary. We report the first case of T‐cell 7.5 + hepatosplenic malignant lymphoma in childhood. Tumour‐specific oligoprobes were developed against the single Vl‐Jl rearrangement of the δ T‐cell receptor (TCR) gene in order to perform minimal residual disease (MRD) studies. Molecular analysis in serial bone marrow samples proved to be of predictive value concerning the clinical outcome. Clonotypic DNA was not detected in peripheral blood during the course of the disease until a refractory terminal leukaemic phase took place 18 months after the diagnosis. This case demonstrates the usefulness of MRU studies to monitor the course of disease in at least some subsets of peripheral T‐cell lymphomas.